论文部分内容阅读
目的探讨131I治疗Graves病合并周期性麻痹的疗效。方法对48例Graves病合并周期性麻痹患者进行131I口服治疗,每克甲状腺组织给予131I治疗剂量为3.70 MBq,于服131I后3个月、6个月、1 a复查血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)、血清促甲状腺素(TSH),测定血钾和观察周期性麻痹恢复情况。结果治疗后3个月、6个月及1a Graves病总治愈率为72.9%、95.8%、100%,周期性麻痹总治愈率为58.3%、79.2%、100%。6个月时治愈率明显高于3个月时(χ2=16.294,χ2=14.737,P<0.05)。结论131I治疗Graves病合并周期性麻痹疗效较好,尽快治愈Graves病是控制周期性麻痹发作的关键。
Objective To investigate the curative effect of 131I on Graves’ disease complicated with periodic paralysis. Methods 48 patients with Graves’ disease complicated with periodic paralysis were treated with 131I orally, and the dosage of 131I per gram of thyroid tissue was 3.70 MBq. Serum free triiodothyronine ammonia was inspected at 3 months, 6 months and 1 year after 131I, Acid (FT3), serum free thyroxine (FT4), serum thyrotropin (TSH), determination of serum potassium and observation of periodic paralysis recovery. Results The total cure rates at 3 months, 6 months and 1a Graves disease were 72.9%, 95.8%, 100%. The total cure rates of periodic paralysis were 58.3%, 79.2%, 100%. At 6 months, the cure rate was significantly higher than 3 months (χ2 = 16.294, χ2 = 14.737, P <0.05). Conclusion 131I treatment of Graves disease with periodic paralysis better curative effect, as soon as possible to cure Graves disease is the key to control the onset of periodic paralysis.